Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use

References

• Schmid FA, Sirotnak FM, Otter GM, et al. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep. 1985;69:551–553.
   PubMedGoogle Scholar
• Sirotnak FM, Schmid FA, Samuels LL, et al. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr. 1987;127–131.
   PubMedGoogle Scholar
• Sirotnak FM, DeGraw JI, Schmid FA, et al. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol. 1984;12:26–30.
   PubMed Web of Science ®Google Scholar
• Kuhnel JM, Chiao JH, Sirotnak FM. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. J Cell Physiol. 2000;184:364–372.
   PubMed Web of Science ®Google Scholar
• Chiao JH, Roy K, Tolner B, et al. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem. 1997;272:11165–11170.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr. 1999;19:91–122.
   PubMed Web of Science ®Google Scholar
• Visentin M, Unal ES, Zhao R, et al. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol. 2013;72:597–606.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–4364.
   PubMed Web of Science ®Google Scholar
• Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6:3493–3498.
   PubMed Web of Science ®Google Scholar
• Krug LM, Azzoli CG, Kris MG, et al. 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res. 2003;9:2072–2078.
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeny K, Dufful S, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther. 2009;86:190–196.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter- Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189.
   PubMed Web of Science ®Google Scholar
• Shustov A, Pro B, Gisselbrecht C. Pralatrexate is effective as second-line treatment following cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstr.; 2010.
   Google Scholar
• Goy A, Pro B, Savage K, et al. Pralatrexate is effective in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with prior ifosfamide, carboplatin, and etoposide (ICE)-based regimens. ASH Annual Meeting Abstracts; 2010.
   Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119:4115–4122.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical–biochemical correlates. J Clin Invest. 1969;48:2140–2155.
   PubMed Web of Science ®Google Scholar
• Haddad PA. Efficacy of short oral leucovorin rescue (SOLR) in managing recurrent pralatrexate (Folotyn) induced mucositis (RPIM) despite dose reduction. Blood (ASH Annual Meeting Abstracts); 2011.
   Google Scholar
• Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma. 2013;54:2448–2451.
   PubMed Web of Science ®Google Scholar
• Tedeschi PM, Kathari YK, Faroogi IN, et al. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer Chemother Pharmacol. 2014;74:1029–1032.
   PubMed Web of Science ®Google Scholar
• Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12(3 Pt 1):924–932.
   Web of Science ®Google Scholar
• Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010;16:3648–3658.
   PubMed Web of Science ®Google Scholar
• Jain S, Jirau-Serrano X, Zullo K, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21:2096–2106.
   PubMed Web of Science ®Google Scholar
• Zullo K, Guo Y, Cooke L, et al. Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015;21:4097–4109.
   PubMed Web of Science ®Google Scholar
• Hoovis ML, Chu MY. Enhancement of the antiproliferative action of 1-β-d-arabinofuranosylcytosine by methotrexate in murine leukemic cells (L5178Y). Cancer Res. 1973;33:521–525.
   PubMed Web of Science ®Google Scholar
• Cadman E, Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest. 1979;64:788–797.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Balvia G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. JCO. 2000;18:2603–2606.
   PubMed Web of Science ®Google Scholar